Welcome to our dedicated page for Macrogenics news (Ticker: MGNX), a resource for investors and traders seeking the latest updates and insights on Macrogenics stock.
MacroGenics, Inc. develops antibody-based therapeutics for cancer, with pipeline work built around monoclonal antibodies, DART and TRIDENT multi-specific molecules, and antibody-drug conjugates. Company news commonly covers clinical and regulatory updates for lorigerlimab, MGC026 and MGC028, including FDA communications tied to study conduct and safety monitoring.
Updates also address financial results, capital-resource commentary, strategic collaborations and licensing economics, including royalty interests tied to ZYNYZ (retifanlimab-dlwr), a PD-1 inhibitor originally developed by MacroGenics and licensed to Incyte.
MacroGenics (NASDAQ: MGNX) agreed to sell its GMP drug substance manufacturing operations to Bora Pharmaceuticals for an upfront payment of $122.5 million, before fees. The deal includes MacroGenics’ Rockville FDA-approved 11,000-liter facility, Frederick warehouse, CDMO operations and about 140 employees, with closing expected in Q3 2026.
Upon closing, Bora will assume clinical and commercial manufacturing, while MacroGenics retains pipeline support through a supply arrangement with Bora.
MacroGenics (Nasdaq: MGNX) entered an expanded royalty purchase agreement with Sagard Healthcare Partners to sell a capped royalty interest in ZYNYZ (retifanlimab-dlwr).
MacroGenics will receive a $60 million upfront payment and may receive an additional 2026 sales-based milestone up to $20 million. Royalties revert when Sagard receives 1.7x its investment by Sept 30, 2032 or 2.0x thereafter. MacroGenics retains other economic interests, including development, regulatory, and commercial milestones.
MacroGenics (NASDAQ: MGNX) announced the FDA has removed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab, a bispecific DART molecule targeting PD-1 and CTLA-4.
The company plans to resume enrollment under a revised protocol with additional risk-mitigation measures for hematologic and cardiac toxicities and remains on track to provide a mid-2026 clinical update.
MacroGenics (NASDAQ: MGNX) reported 2025 results, operational updates and 2026 data timelines. Key milestones include initial Phase 1 data for MGC026 in mid-2026, initial Phase 1 data for MGC028 in H2 2026, and an IND submission for MGC030 targeted for 3Q 2026. Cash, cash equivalents and marketable securities were $189.9M as of December 31, 2025, with a stated cash runway into late 2027. 2025 revenue totaled $149.5M, R&D expense was $147.2M, and net loss was $74.6M. The company noted partnership milestone upside with Gilead, Sanofi and Incyte.
MacroGenics (Nasdaq: MGNX) announced participation in multiple investor conferences in March 2026, with CEO Eric Risser delivering hybrid presentations and fireside chats and management holding one-on-one meetings.
Events include TD Cowen (Mar 3, 3:10 pm ET), Leerink Partners (Mar 10, 1:40 pm ET), The Citizens Life Sciences (Mar 11, 10:45 am ET) and Barclays (Mar 12, 10:00 am ET). Webcasts will be available via the company’s Investor Relations "Events & Presentations" page, and archived replays will remain on the site for 30 days.
MacroGenics (NASDAQ: MGNX) said the FDA placed a partial clinical hold on its Phase 2 LINNET study of lorigerlimab in gynecologic cancers effective Feb 23, 2026.
No new patients may be enrolled until the hold is lifted; current participants may continue to receive study drug. Four patients experienced serious safety events, including one Grade 5 event. To date, 41 participants have been dosed at 6 mg/kg every three weeks.
MacroGenics (Nasdaq: MGNX) announced that Eric Risser, President and CEO, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025 at 7:55 am ET in Miami, FL.
A live webcast will be available via the company's Investor Relations "Events & Presentations" page and an archived replay will be maintained on the website for 30 days.
MacroGenics (NASDAQ: MGNX) reported third-quarter 2025 results and corporate updates on Nov 12, 2025. The company had $146.4M in cash and marketable securities as of Sept 30, 2025, and expects to receive $75M in partnering payments from Sanofi and Gilead by year-end, extending cash runway into late 2027. Total revenue was $72.8M for Q3 2025 vs. $110.7M in Q3 2024. MacroGenics will stop developing lorigerlimab in second-line mCRPC after interim LORIKEET data but will continue the LINNET Phase 2 study in ovarian/gynecologic cancers. ADC programs MGC026, MGC028 and preclinical MGC030 remain active; an IND for MGC030 is planned for 2026.
MacroGenics (Nasdaq: MGNX) announced that President and CEO Eric Risser will participate in a fireside chat at the Stifel 2025 Healthcare Conference on Thursday, November 13, 2025 at 4:00 PM ET in New York.
A live webcast will be available via the company's Investor Relations "Events & Presentations" page and an archived replay will be maintained on the website for 30 days.
MacroGenics (NASDAQ:MGNX), a biopharmaceutical company specializing in antibody-based cancer therapeutics, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. President & CEO Eric Risser will deliver a presentation on Monday, September 8, 2025, at 11:30am ET in New York.
Investors can access the presentation webcast through the company's investor relations website, with a replay available for 30 days following the event.